1 - 25 of 38 results for author:"Tuveson D.A." in Literature citations
Results Customize
› Repeat search in UniProtKB (75)
| The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Perez-Mancera P.A., Rust A.G., van der Weyden L., Kristiansen G., Li A., Sarver A.L., Silverstein K.A., Grutzmann R., Aust D., Rummele P. et al. Nature 486:266-270(2012) · Mapped (14) |
| Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. Cook N., Frese K.K., Bapiro T.E., Jacobetz M.A., Gopinathan A., Miller J.L., Rao S.S., Demuth T., Howat W.J., Jodrell D.I. et al. J. Exp. Med. 209:437-444(2012) · Mapped (17) |
| Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. Maniati E., Bossard M., Cook N., Candido J.B., Emami-Shahri N., Nedospasov S.A., Balkwill F.R., Tuveson D.A., Hagemann T. J. Clin. Invest. 121:4685-4699(2011) · Mapped (28) |
| C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Karreth F.A., Frese K.K., DeNicola G.M., Baccarini M., Tuveson D.A. Cancer Discov 1:128-136(2011) · Mapped (17) |
| In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Karreth F.A., Tay Y., Perna D., Ala U., Tan S.M., Rust A.G., DeNicola G., Webster K.A., Weiss D., Perez-Mancera P.A. et al. Cell 147:382-395(2011) · Mapped (22) |
| SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Pearson H.B., Perez-Mancera P.A., Dow L.E., Ryan A., Tennstedt P., Bogani D., Elsum I., Greenfield A., Tuveson D.A., Simon R. et al. J. Clin. Invest. 121:4257-4267(2011) · Mapped (116) |
| Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Caldwell M.E., DeNicola G.M., Martins C.P., Jacobetz M.A., Maitra A., Hruban R.H., Tuveson D.A. Oncogene 31:1599-1608(2012) · Mapped (6) |
| Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S. et al. Nature 475:106-109(2011) · Mapped (9) |
| Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Froeling F.E., Feig C., Chelala C., Dobson R., Mein C.E., Tuveson D.A., Clevers H., Hart I.R., Kocher H.M. Gastroenterology 141:1486-97, 2011:1497.e1-14(2011) · Mapped (9) |
| Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., Jones D., Lin M.L., Teague J. et al. Nature 469:539-542(2011) · UniProtKB (74) |
| Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Skoulidis F., Cassidy L.D., Pisupati V., Jonasson J.G., Bjarnason H., Eyfjord J.E., Karreth F.A., Lim M., Barber L.M., Clatworthy S.A. et al. Cancer Cell 18:499-509(2010) · Mapped (25) |
| C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Karreth F.A., DeNicola G.M., Winter S.P., Tuveson D.A. Mol. Cell 36:477-486(2009) · Mapped (13) |
| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D. et al. Science 324:1457-1461(2009) · Mapped (19) |
| A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Flaherty K.T., Schiller J., Schuchter L.M., Liu G., Tuveson D.A., Redlinger M., Lathia C., Xia C., Petrenciuc O., Hingorani S.R. et al. Clin. Cancer Res. 14:4836-4842(2008) · Mapped (3) |
| Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Cancer Res. 67:9518-9527(2007) · Mapped (8) |
| Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Kissil J.L., Walmsley M.J., Hanlon L., Haigis K.M., Bender Kim C.F., Sweet-Cordero A., Eckman M.S., Tuveson D.A., Capobianco A.J., Tybulewicz V.L. et al. Cancer Res. 67:8089-8094(2007) · Mapped (13) |
| The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Thomas R.M., Toney K., Fenoglio-Preiser C., Revelo-Penafiel M.P., Hingorani S.R., Tuveson D.A., Waltz S.E., Lowy A.M. Cancer Res. 67:6075-6082(2007) · Mapped (3) |
| Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Shaw A.T., Meissner A., Dowdle J.A., Crowley D., Magendantz M., Ouyang C., Parisi T., Rajagopal J., Blank L.J., Bronson R.T. et al. Genes Dev. 21:694-707(2007) · Mapped (38) |
| Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Izeradjene K., Combs C., Best M., Gopinathan A., Wagner A., Grady W.M., Deng C.X., Hruban R.H., Adsay N.V., Tuveson D.A. et al. Cancer Cell 11:229-243(2007) · Mapped (23) |
| Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Zhang J., Liu Y., Beard C., Tuveson D.A., Jaenisch R., Jacks T.E., Lodish H.F. Blood 109:5238-5241(2007) · Mapped (7) |
| Restoration of p53 function leads to tumour regression in vivo. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Nature 445:661-665(2007) · Mapped (18) |
| Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. King A.J., Patrick D.R., Batorsky R.S., Ho M.L., Do H.T., Zhang S.Y., Kumar R., Rusnak D.W., Takle A.K., Wilson D.M. et al. Cancer Res. 66:11100-11105(2006) · Mapped (1) |
| Ductal pancreatic cancer in humans and mice. Tuveson D.A., Hingorani S.R. Cold Spring Harb. Symp. Quant. Biol. 70:65-72(2005) · Mapped (30) |
| Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Braun B.S., Archard J.A., Van Ziffle J.A., Tuveson D.A., Jacks T.E., Shannon K. Blood 108:2041-2044(2006) · Mapped (7) |
| Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Tuveson D.A., Zhu L., Gopinathan A., Willis N.A., Kachatrian L., Grochow R., Pin C.L., Mitin N.Y., Taparowsky E.J., Gimotty P.A. et al. Cancer Res. 66:242-247(2006) · Mapped (13) |